Synopsys stock tests $389 support after Executive Chair Aart de Geus sells large stake

Synopsys stock tests $389 support after Executive Chair Aart de Geus sells large stake
Synopsys drops 5.5% to $415.41 today

Synopsys (SNPS) stock is trading at $415.41, falling 5.5% on the day. The price has moved lower and currently sits below its key moving averages.

SNPS price prediction
24H 0.12%
$468.09
48H -0.83%
$463.61
7D -0.85%
$463.54
1M 1.69%
$475.43
3M 9.55%
$512.17
6M -9.56%
$422.82
12M 11.87%
$523.01
Current price: $467.51 -22.6800 4.63%
Closed 10/30
Daily range 460.26 Arrow from to Icon 473.66
Weekly range 432.94 Arrow from to Icon 491.23
Loading...

Highlights

  • Synopsys delivered Q3 FY 2026 revenue of $2.48 billion, up 42% year over year and above analyst predictions.
  • Executive Chair Aart de Geus sold 25,000 shares for $11.1 million, introducing short-term supply into Synopsys stock.
  • Shares of Synopsys are trading below key moving averages, with technical indicators showing strong seller control and a range of $389 to $441.82 projected for the next few days.

Growth beats estimates yet share sale heightens immediate supply risk

Synopsys reported strong Q3 FY 2026 results, generating $2.48 billion in revenue, a 42% annual increase that exceeded Wall Street expectations, according to Finance Yahoo. This solid operational performance confirmed substantial growth and beat analyst estimates, providing a supportive fundamental backdrop. However, on August 28, 2026, Executive Chair Aart de Geus sold 25,000 shares for a total of $11.1 million, as reported by Investing.com, which may have introduced short-term supply pressure on the stock.

Synopsys asset chart
Synopsys price dynamics. Source: TradingView.

Oversold signals and resistance barriers reinforce intraday bearish bias

On the technical front, SNPS is trading below the MA-20 at $442.69 and MA-50 at $421.97 on the hourly chart, and well under the MA-200 at $446.86 on the daily timeframe. The Ichimoku Kijun acts as immediate resistance at $435.76. Momentum indicators show strong negative pressure: ADX and MACD are positioned from Sell to Neutral, while the RSI at 34.43, Stochastic RSI, CCI, and Bull/Bear Power all indicate oversold conditions with clear seller dominance. The Awesome Oscillator is in strong Sell territory, reflecting broad alignment among oscillators and supporting the prevailing intraday momentum.

Downside risk remains elevated amid consolidation scenario

In the next two to three trading days, SNPS price is likely to fluctuate between $389 and $441.82 based on typical volatility bands. The probability of an upside move is 43%, while the likelihood of continued downside stands at 57%, suggesting downside risks remain elevated in the short term. The baseline scenario points to a consolidation within this corridor. A sustained move above $435.76 would open the way to a bullish scenario, while a breach below $389 would confirm renewed bearish momentum.

Viktoras Karapetjanc, analyst at Traders Union, notes that Synopsys continues to deliver impressive top-line growth, far outpacing estimates and reinforcing his confidence in its long-term fundamentals. He acknowledges that technicals show sellers are in control near-term, yet believes recent insider selling may fuel only temporary volatility rather than alter the growth story. Karapetjanc sees strong core momentum, supported by the outsized revenue jump, as important for regaining investor sentiment if resistance levels are reclaimed. “I view this dip as a potential opportunity for patient investors, provided Synopsys can sustain its growth trajectory and reclaim critical technical levels.”

Earlier, analysts noted that Synopsys shares were consolidating sideways following robust earnings and revised guidance, amid mixed technical signals and integration concerns. Current price action underscores increasing downside risk and broad selling momentum, making a sustained move above $435.76 a pivotal level to watch for any potential reversal.

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.